On October 20, 2016, Fukunaga, Hirofumi; Dozono, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Nagano, Akio published a patent.Computed Properties of 445490-78-8 The title of the patent was Therapeutic or diagnostic agents for integrin-related disease comprising nitrogen-containing compounds metal complexes. And the patent contained the following:
Disclosed is a therapeutic or diagnostic agents for integrin-related disease comprising metal complexes with nitrogen-containing compounds The nitrogen-containing compounds are, represented by formula I [A1 = chelate group; R1, R2 = H, (un)substituted C1-6 alkyl, amino protective group; Z1-Z5 = N, CR3; R3 = H, halo, (un)substituted C1-6 alkyl, (un)substituted pyridinyl-containing sulfonyl group; L1 = [NR13(CR14CR15O)qCR16CO]r; L2, L3 = (un)substituted C1-6 alkylene; R13 = H, (un)substituted C1-6 alkyl, amino protective group; R14, R15 = H, (un)substituted C1-6 alkyl; R16 = H, (un)substituted C1-6 alkyl, aromatic or heterocycle amide-containing group]. Thus, reacting tetrahydronaphthyridine terminal-containing cysteic acid (preparation given) with tri-tert-Bu 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate, and deprotecting tert-Bu groups with aqueous LiOH, gave tetraazacyclododecane ring-containing tricarboxylic acid. The tetraazacyclododecane ring-containing tricarboxylic acid can give complexes with radioactive metals showing high concentration and retention in the cancer cells. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Computed Properties of 445490-78-8
The Article related to heterocycle metal complex preparation integrin disorder cancer radiopharmaceutical diagnostic, Radiation Biochemistry: Disease Diagnosis and Therapy and other aspects.Computed Properties of 445490-78-8
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem